The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
|Articles|October 3, 2006
Robert Davidson
Robert Davidson
Advertisement
Robert is Managing Editor of Applied Clinical Trials magazine. He received his B.S. degree in Magazine Journalism from the University of Maryland, College Park. Robert has significant experience in medical/scientific peer-review publishing, including a number of years with the IEEE Journals Department, where he managed 15 titles such as Transactions on Medical Imaging and Transactions on Nuclear Science. Earlier, he was an editorial researcher with National Magazine Award-winning IEEE Spectrum magazine. In 2003, he wrote a CME monograph covering COPD that was sponsored by GlaxoSmithKline. He has been with ACT for the past 3 years. In between his time with trade publications, Robert combined a personal interest and avocation as an editor with Field & Stream magazine, and he later gained public relations experience as a PR manager with Cendant Corporation.
Advertisement
Related to this article
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Syneos Health and Optum outline a joint model for trial planning, recruitment and site access, with no financial terms or timelines disclosed.
AstraZeneca and Oracle Outline AI Collaboration for Clinical Trial Recruitment and Safety Monitoring
What sponsors and sites should know about the AstraZeneca-Oracle AI collaboration on trial recruitment, safety monitoring and data governance.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
2
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
3
Where AI Governance in Clinical Development Falls Short
4
Syneos Health, Optum Partner on Adaptive Clinical Development Model
5